 Connection
Robert Weinstein to Osteoporosis
This is a "connection" page, showing publications Robert Weinstein has written about Osteoporosis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.844 |
|
|
|
-
Weinstein RS. Glucocorticoid-induced osteoporosis and osteonecrosis. Endocrinol Metab Clin North Am. 2012 Sep; 41(3):595-611.
Score: 0.368
-
Weinstein RS. Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med. 2011 Jul 07; 365(1):62-70.
Score: 0.347
-
Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P, Weinstein RS. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5?mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res. 2010 Oct; 25(10):2239-50.
Score: 0.329
-
Jain N, Weinstein RS. Giant osteoclasts after long-term bisphosphonate therapy: diagnostic challenges. Nat Rev Rheumatol. 2009 Jun; 5(6):341-6.
Score: 0.300
-
Weinstein RS, Jia D, Powers CC, Stewart SA, Jilka RL, Parfitt AM, Manolagas SC. The skeletal effects of glucocorticoid excess override those of orchidectomy in mice. Endocrinology. 2004 Apr; 145(4):1980-7.
Score: 0.206
-
Ambrogini E, Que X, Wang S, Yamaguchi F, Weinstein RS, Tsimikas S, Manolagas SC, Witztum JL, Jilka RL. Oxidation-specific epitopes restrain bone formation. Nat Commun. 2018 06 06; 9(1):2193.
Score: 0.140
-
Weinstein RS. Glucocorticoids, osteocytes, and skeletal fragility: the role of bone vascularity. Bone. 2010 Mar; 46(3):564-70.
Score: 0.075
-
Weinstein RS, Chen JR, Powers CC, Stewart SA, Landes RD, Bellido T, Jilka RL, Parfitt AM, Manolagas SC. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest. 2002 Apr; 109(8):1041-8.
Score: 0.046
-
Martin-Millan M, Almeida M, Ambrogini E, Han L, Zhao H, Weinstein RS, Jilka RL, O'Brien CA, Manolagas SC. The estrogen receptor-alpha in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone. Mol Endocrinol. 2010 Feb; 24(2):323-34.
Score: 0.020
-
Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology. 2005 Mar; 146(3):1226-35.
Score: 0.014
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|